KR960013435B1 - 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물 - Google Patents

바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물 Download PDF

Info

Publication number
KR960013435B1
KR960013435B1 KR1019880003033A KR880003033A KR960013435B1 KR 960013435 B1 KR960013435 B1 KR 960013435B1 KR 1019880003033 A KR1019880003033 A KR 1019880003033A KR 880003033 A KR880003033 A KR 880003033A KR 960013435 B1 KR960013435 B1 KR 960013435B1
Authority
KR
South Korea
Prior art keywords
dsrna
aids
hiv
mismatched
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019880003033A
Other languages
English (en)
Korean (ko)
Other versions
KR880010777A (ko
Inventor
에이. 카터 윌리암
Original Assignee
헤미스페르스 바이오파마, 인코오포레이티드
로이 디. 우르다노프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헤미스페르스 바이오파마, 인코오포레이티드, 로이 디. 우르다노프 filed Critical 헤미스페르스 바이오파마, 인코오포레이티드
Publication of KR880010777A publication Critical patent/KR880010777A/ko
Application granted granted Critical
Publication of KR960013435B1 publication Critical patent/KR960013435B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1019880003033A 1987-03-23 1988-03-22 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물 Expired - Fee Related KR960013435B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2882387A 1987-03-23 1987-03-23
US028,823 1987-03-23
US028823 1987-03-23
US125,097 1987-11-25
US07/125,097 US4950652A (en) 1987-03-23 1987-11-25 dsRNAs for combination therapy in the treatment of viral diseases
US125097 1987-11-25

Publications (2)

Publication Number Publication Date
KR880010777A KR880010777A (ko) 1988-10-24
KR960013435B1 true KR960013435B1 (ko) 1996-10-05

Family

ID=26704119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003033A Expired - Fee Related KR960013435B1 (ko) 1987-03-23 1988-03-22 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물

Country Status (21)

Country Link
US (1) US4950652A (enExample)
EP (1) EP0286224B1 (enExample)
JP (1) JP2656938B2 (enExample)
KR (1) KR960013435B1 (enExample)
CN (1) CN1049357C (enExample)
AU (1) AU1256288A (enExample)
CA (1) CA1316832C (enExample)
DE (1) DE3876125T2 (enExample)
DK (1) DK156688A (enExample)
ES (1) ES2066782T3 (enExample)
FI (1) FI881305A7 (enExample)
GR (1) GR3006340T3 (enExample)
HU (1) HUT46542A (enExample)
IE (1) IE63823B1 (enExample)
IL (1) IL85646A (enExample)
NO (1) NO881246L (enExample)
NZ (1) NZ223868A (enExample)
OA (1) OA08724A (enExample)
PH (1) PH23333A (enExample)
PT (1) PT87039B (enExample)
RU (1) RU2016572C1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5091374A (en) * 1987-07-17 1992-02-25 Hem Research Inc. Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
US4960592A (en) * 1989-04-17 1990-10-02 Lanocare Laboratories Lanolin and lanolin oil skin treatment composition
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
AU671800B2 (en) * 1991-04-16 1996-09-12 Hem Pharmaceuticals Corp. Abrogation of viral resistance to nucleoside analogues by double-stranded RNAs
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
WO1993001717A1 (en) * 1991-07-16 1993-02-04 Hem Pharmaceuticals Corp. Modulation and diagnosis of cytokine dysfunctions
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
RU2123339C1 (ru) * 1996-06-18 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Противовирусное средство
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
SI9820003A (sl) * 1997-01-17 1999-06-30 Icn Pharmaceuticals, Inc. Zdravljenje bolezni povezano s citokini
LT4475B (lt) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Informacinės ribonukleino rūgšties panaudojimas vaistinėse medžiagose, skirtose padidinti šios ribonukleino rūgšties koduojamo baltymo kiekį paciento ląstelėse
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
FR2766711B1 (fr) * 1997-08-04 2001-02-02 Sod Conseils Rech Applic Produit comprenant au moins un arn double brin en association avec au moins un devire du 6-benzyluracile pour une utilisation therapeutique simultanee, separee ou etalee dans le temps
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
RU2172631C2 (ru) * 1999-10-08 2001-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Индуктор интерферона пролонгированного действия
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US20050070489A1 (en) * 2001-12-14 2005-03-31 Carter William A Use of dsrnas in strategic therapeutic intervention of highly active antiretroviral therapy
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20050137154A1 (en) * 2003-05-16 2005-06-23 Hemispherx Biopharma Treating server acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
US20050113292A1 (en) * 2003-07-18 2005-05-26 Vanderbilt University Compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like
KR101280094B1 (ko) * 2003-08-11 2013-06-28 사이단호진한다이비세이부쯔뵤우겐큐우카이 점막 면역을 유도할 수 있는 보강제를 함유한 신규한 백신
RU2272631C2 (ru) * 2004-04-20 2006-03-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Синергическая композиция для ингибирования вич
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
ES2536103T3 (es) * 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CA2644670A1 (en) * 2006-03-08 2008-05-08 Hemispherx Biopharma Inc. Broad spectrum immune and antiviral gene modulation by oral interferon
EP2214668A1 (en) * 2007-10-29 2010-08-11 Cipla Limited Novel antiretroviral combination
JP2011525169A (ja) * 2008-02-15 2011-09-15 へミスフェリックス・バイオファーマ，インコーポレーテッド Ｔｏｌｌ様受容体３の選択的アゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
DE3650130T3 (de) * 1985-03-16 2003-07-24 The Wellcome Foundation Ltd., London Antivirale Nukleoside.
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
JPS6425A (en) 1989-01-05
GR3006340T3 (enExample) 1993-06-21
DK156688A (da) 1988-09-24
FI881305L (fi) 1988-09-24
RU2016572C1 (ru) 1994-07-30
IE880839L (en) 1988-09-23
PT87039B (pt) 1992-11-30
IL85646A (en) 1993-05-13
IE63823B1 (en) 1995-06-14
HUT46542A (en) 1988-11-28
DE3876125D1 (de) 1993-01-07
IL85646A0 (en) 1988-08-31
CN88101606A (zh) 1988-12-28
NO881246L (no) 1988-09-26
NO881246D0 (no) 1988-03-21
CN1049357C (zh) 2000-02-16
CA1316832C (en) 1993-04-27
PH23333A (en) 1989-07-14
EP0286224A3 (en) 1988-12-07
NZ223868A (en) 1991-02-26
KR880010777A (ko) 1988-10-24
EP0286224B1 (en) 1992-11-25
DE3876125T2 (de) 1993-06-09
ES2066782T3 (es) 1995-03-16
OA08724A (fr) 1989-03-31
EP0286224A2 (en) 1988-10-12
FI881305A0 (fi) 1988-03-18
DK156688D0 (da) 1988-03-22
FI881305A7 (fi) 1988-09-24
US4950652A (en) 1990-08-21
JP2656938B2 (ja) 1997-09-24
PT87039A (pt) 1988-04-01
AU1256288A (en) 1988-09-22

Similar Documents

Publication Publication Date Title
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
US5736527A (en) Method of treating HIV in humans by administration of ddI and hydroxycarbamide
EP0291633A1 (en) Use of 3'-azido-3'-deoxythymidine in the treatment or prophylaxis of human retroviral infections
EP0994702B1 (en) Medicament comprising adenosine
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
CZ298008B6 (cs) Farmaceutický prostredek
Zeidner et al. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine
AU681350B2 (en) Inhibitiion of retrovirus infection
AU660673B2 (en) Treatment of human viral infection by dsRNA combined with viral inhibitors
US5059592A (en) Composition for prevention and (or) treatment of AIDS
IE930485A1 (en) Antidepressant agents with a rapid onset of action
WO1992016200A1 (en) The use of hydroxamic acid derivatives to inhibit viral replication
HU208254B (en) Hiv inhibition by applying synergetic combinations of nucleoside derivatives
WO1995028940A1 (en) Methods for inhibiting human immunodeficiency virus
JPH08208502A (ja) 抗エイズウイルス剤の効果増強剤
WO1997000685A1 (en) Use of substituted pentose or hexose derivates in the treatment of aids and aids related neoplastic disorders
US5229368A (en) Composition for prevention and (or) treatment of Aids
AU743942B2 (en) Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
JPH07509442A (ja) ウィルス病処置でのホスホリル化フラボノイド類
JPH01172321A (ja) ６−０−置換−Ｄ−グルコ−δ−ラクタムを含有する抗ウイルス剤
Sarin et al. Lymphadenopathy-Associated Virus) by
WO1995017875A2 (en) MIXTURES OF DIDEOXYNUCLEOSIDES AND D-ASPARTIC ACID β-HYDROXAMATE FOR INHIBITING RETROVIRAL SPREAD
HU203971B (en) Process for producing synergetic combination pharmaceutical compositions comprising 3'-azido-3'-deoxythymidine and one more active ingredient
DE3821676A1 (de) Verwendung von avaron oder avaron-derivaten in kombination mit 3'-azido-3'-deoxythymidin zur antiviralen therapie

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20020927

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20031006

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20031006

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000